-
2023-504226-18-00
5
2022-11-30
NMDAR or LGI1 mediated autoimmune Encephalitis
-
2023-505766-28-00
10
2022-10-10
Hereditary angioedema
-
2023-503465-33-00
5
2020-07-03
Cholestasis
-
2024-518223-29-00
4
2020-03-10
Advanced or metastatic untreated EGFR mutation positive NSCLC
-
2025-521666-10-01
4
2026-06-08
Mantle Cell Lymphoma
-
2025-523428-39-00
4
2026-06-05
Mantle Cell Lymphoma
-
2025-521976-80-00
4
2026-05-28
Relapsed or Refractory
Multiple Myeloma (RRMM)
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-524265-24-00
5
2026-05-21
Dyslipidemia at High to Very High Cardiovascular Risk
-
2025-521074-34-00
4
2026-05-15
Allogeneic peripheral hematopoietic stem cell transplant
-
2024-520441-23-00
5
2026-05-13
Overweight or obesity, and type 2 diabetes
-
2025-523367-38-00
5
2026-05-11
Postoperative inflammation after cataract surgery
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-523804-62-00
5
2026-04-28
Obesity
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2025-521416-19-00
4
2026-03-12
Recurrence of Clostridioides difficile Infection
-
2025-521319-38-00
4
2026-03-11
metastatic colorectal cancer
-
2025-522074-37-00
4
2026-02-19
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension Associat
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2024-519706-13-00
6
2026-01-26
Patients with Stable or Unstable coronary syndromes who have undergone
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci